Brent L. Larson is CFO & EVP +1 at NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB). They have made 3 open-market trades across 2 companies since 2006, most recently 2015-12-01.
CIK 0001195766
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $8K since 2006, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NAVB | SELL · 10b5-1 | 2015-12-01 | 2015-12-03 | $1.50 | $19K | -10.6% | -5.1% | -5.1% |
| NAVB | SELL · 10b5-1 | 2015-11-02 | 2015-11-04 | $1.98 | $25K | -10.6% | -5.1% | -5.1% |
| NAVB | SELL · 10b5-1 | 2015-10-01 | 2015-10-05 | $2.27 | $28K | -10.6% | -5.1% | -5.1% |
| NAVB | SELL · 10b5-1 | 2015-09-01 | 2015-09-02 | $1.88 | $24K | -10.6% | -5.1% | -5.1% |
| NAVB | SELL · 10b5-1 | 2015-08-03 | 2015-08-05 | $1.71 | $21K | -10.6% | -5.1% | -5.1% |
| NAVB | SELL · 10b5-1 | 2015-07-01 | 2015-07-02 | $1.61 | $20K | -10.6% | -5.1% | -5.1% |
| NAVB | SELL · 10b5-1 | 2015-06-01 | 2015-06-02 | $1.24 | $16K | -10.6% | -5.1% | -5.1% |
| NAVB | SELL · 10b5-1 | 2015-05-01 | 2015-05-05 | $1.33 | $17K | -10.6% | -5.1% | -5.1% |
| NAVB | SELL · 10b5-1 | 2015-04-01 | 2015-04-03 | $1.58 | $32K | -10.6% | -5.1% | -5.1% |
| NAVB | SELL | 2014-03-10 | 2014-03-11 | $1.96 | $81K | -10.6% | -5.1% | -5.1% |
| NAVB | BUY | 2013-11-08 | 2013-11-08 | $1.39 | $7K | -10.6% | -5.1% | -5.1% |
| NEOP | SELL · 10b5-1 | 2011-11-01 | 2011-11-02 | $2.75 | $34K | N/A | N/A | N/A |
| NEOP | BUY | 2006-05-12 | 2006-05-15 | $0.27 | $1K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.